Herombopag Treated T-DM1 Induced Platelet Reduction

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study ID
NCT07257809
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Herombopag Olamine Tablets — DRUG
    Herombopag 7.5 mg po qd，d1-14

Study Details

This is a single-arm study planned to enroll 56 breast cancer patients who experienced grade 2 or higher thrombocytopenia following prior chemotherapy and achieved normalization (platelet count ≥100 × 109/L and ≥200 × 109/L) through intervention.

Key Dates

Start date
Oct 13, 2025
Status verified
Oct 2025
Primary completion
Sep 26, 2026
Completion
Sep 26, 2027

Study Design

Enrollment
56 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group A
    Herombopag， initial dose 7.5 mg po qd d1-14

Primary Outcome Measure

Proportion of grade I thrombocytopenia according to CTCAE4.0 [ Time Frame: From enrollment to the end of treatment at 6 weeks ]

Central Contacts

Related Studies